E.g. Moderna protocol:
https://www.modernatx.com/sites/default/files/mRNA-1273-P301...
"To be considered as a case of COVID-19 for the evaluation of the Primary Efficacy Endpoint, the following criteria must be met:
- The participant must have experienced at least TWO of the following systemic symptoms: Fever (≥ 38ºC), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR
- The participant must have experienced at least ONE of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, OR clinical or radiographical evidence of pneumonia; AND
- The participant must have at least one NP swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR."
In some other protocols it's not written in an easily quotable way but spread through the text and tables, but if you analyze the protocols carefully, the goal is the same: it's the vaccinated and symptomatic that are counted and compared with the symptomatic counted in the placebo group.
So whenever you saw "protection" up to now it was implicit it's the protection from the disease as defined above. Not the sterilizing immunity.
Moderna's announcement is also explicit in mentioning so defined "primary endpoint":
https://investors.modernatx.com/news-releases/news-release-d...
"The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine."
We should eventually know more, but we still don't have that information.